Results 301 to 310 of about 122,915 (346)
Some of the next articles are maybe not open access.

Scleroderma

Journal of the American Academy of Dermatology, 1987
After a review of some pathogenetic and pathologic aspects of scleroderma, the experimental effects of a group of agents that can inhibit the formation of connective tissue, especially the biosynthesis of collagen, are mentioned. These substances were transferred to clinical therapy of scleroderma.
openaire   +2 more sources

Keloidal scleroderma.

Clinical and experimental dermatology, 2003
A 53-year-old woman with systemic sclerosis developed numerous cutaneous nodules, resembling keloids, on her anterior chest wall. The nodules failed to respond to therapy with topical steroid, calcipotriol, or extended photochemotherapy. This is a rare, disfiguring variant of scleroderma, unresponsive to treatment, and poorly understood.
Ling, T. C.   +4 more
openaire   +4 more sources

Scleroderma

2008
The prototypic autoimmune diseases involving skin (lupus, dermatomyositis) typically result in epithelial injury and autoantibodies to characteristic cellular antigens. Disease-specific autoantibodies are also found in scleroderma, but scleroderma is different from other cutaneous autoimmune diseases because epithelial injury does not occur.
openaire   +2 more sources

Scleroderma‐like skin changes induced by checkpoint inhibitor therapy

Journal of cutaneous pathology, 2018
Checkpoint inhibitors have emerged as beneficial therapies in many different types of malignancy. The most common toxicities of checkpoint inhibitors are immune‐related adverse events (irAEs).
B. J. Tjarks   +3 more
semanticscholar   +1 more source

Scleroderma epidemiology

Rheumatic Disease Clinics of North America, 1996
Evidence from multiple sources indicates that SSc does not occur randomly in the population; there are particular groups who are at greater risk. The overall incidence rate of SSc in the adult population of the United States is approximately 20 per million per year; this rate has increased from 1944 to 1973, but has been relatively stable since that ...
openaire   +3 more sources

Supportive Use of Adipose-Derived Stem Cells in Cell-Assisted Lipotransfer for Localized Scleroderma

Plastic and Reconstructive Surgery, 2018
Background: The authors aimed to analyze factors related to lipotransfer for localized scleroderma, and to explore the feasibility of cell-assisted lipotransfer for localized scleroderma treatment.
Bo Chen   +6 more
semanticscholar   +1 more source

Scleroderma esophagus

Dysphagia, 1990
Scleroderma (systemic sclerosis) is a connective tissue disorder characterized by thickening and fibrosis of the skin and visceral involvement that may include the heart, lungs, kidneys, and gastrointestinal tract. At least 40-50% of patients with scleroderma experience esophageal symptoms such as heartburn and dysphagia, while up to 90% of patients ...
S R, Fulp, D O, Castell
openaire   +2 more sources

Juvenile Scleroderma

Indian Journal of Pediatrics, 2023
Localised scleroderma and systemic sclerosis are rare chronic fibrosing disorders seen in children, and are collectively referred to as Juvenile Scleroderma. Histopathology of the two forms is non-distinct but they differ in terms of vasculopathy, internal organ involvement, morbidity and mortality.
openaire   +2 more sources

Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

Clinical reviews in allergy and immunology, 2021
Ming Zhao   +4 more
semanticscholar   +1 more source

Pediatric scleroderma

Seminars in Cutaneous Medicine and Surgery, 1998
Scleroderma is a diverse group of conditions which have in common fibrosis of skin and other tissues. Although less common in children than in adults, these conditions are an important cause of morbidity and occasional mortality when they occur in the pediatric population.
openaire   +2 more sources

Home - About - Disclaimer - Privacy